An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas
Current Treatment Options in Oncology · 2024-07 · 25 (7) · 952-991
DOI: 10.1007/s11864-024-01211-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 19.06.2024. Verfasst von Georgios M Stergiopoulos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Glioma, Oncolytic Viruses, Brain Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 286 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
OPINION STATEMENT: Malignant gliomas are common central nervous system tumors that pose a significant clinical challenge due to the lack of effective treatments. Glioblastoma (GBM), a grade 4 malignant glioma, is the most prevalent primary malignant brain tumor and is associated with poor prognosis. Current clinical trials are exploring various strategies to combat GBM, with oncolytic viruses (OVs) appearing particularly promising. In addition to ongoing and recently completed clinical trials, one OV (Teserpaturev, Delytact®) received provisional approval for GBM treatment in Japan. OVs are designed to selectively target and eliminate cancer cells while promoting changes in the tumor microenvironment that can trigger and support long-lasting anti-tumor immunity. OVs offer the potential to remodel the tumor microenvironment and reverse systemic immune exhaustion. Additionally, an increasing number of OVs are armed with immunomodulatory payloads or combined with immunotherapy approaches in an effort to promote anti-tumor responses in a tumor-targeted manner. Recently completed oncolytic virotherapy trials can guide the way for future treatment individualization through patient preselection, enhancing the likelihood of achieving the highest possible clinical success. These trials also offer valuable insight into the numerous challenges inherent in malignant glioma treatment, some of which OVs can help overcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA.
- Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA. concilio.susanna@mayo.edu.
- Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA. galanis.evanthia@mayo.edu.
- Department of Oncology, Mayo Clinic, Rochester, MN, USA. galanis.evanthia@mayo.edu.
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Stergiopoulos, G. M., Concilio, S. C., & Galanis, E. (2024). An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas. Current Treatment Options in Oncology, 25(7), 952-991. https://doi.org/10.1007/s11864-024-01211-6
Vancouver
Stergiopoulos GM, Concilio SC, Galanis E. An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas. Current Treatment Options in Oncology. 2024;25(7):952-991. doi:10.1007/s11864-024-01211-6
BibTeX
@article{Stergiopoulos2024,
author = {Stergiopoulos, Georgios M and Concilio, Susanna C and Galanis, Evanthia},
title = {An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas},
journal = {Current Treatment Options in Oncology},
year = {2024},
volume = {25},
number = {7},
pages = {952--991},
doi = {10.1007/s11864-024-01211-6}
}
EUVIMED